Nicotine Addiction - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 55 | Publisher: Global Research & Data Services
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Nicotine Addiction - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Nicotine Addiction - Pipeline Review, H1 2015’, provides an overview of the Nicotine Addiction’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nicotine Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nicotine Addiction and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nicotine Addiction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Nicotine Addiction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Nicotine Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Nicotine Addiction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Nicotine Addiction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Nicotine Addiction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Nicotine Addiction Overview 7
Therapeutics Development 8
Pipeline Products for Nicotine Addiction - Overview 8
Pipeline Products for Nicotine Addiction - Comparative Analysis 9
Nicotine Addiction - Therapeutics under Development by Companies 10
Nicotine Addiction - Therapeutics under Investigation by Universities/Institutes 11
Nicotine Addiction - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Nicotine Addiction - Products under Development by Companies 14
Nicotine Addiction - Products under Investigation by Universities/Institutes 15
Nicotine Addiction - Companies Involved in Therapeutics Development 16
AbbVie Inc. 16
Astraea Therapeutics, LLC 17
Embera NeuroTherapeutics, Inc. 18
FORUM Pharmaceuticals Inc. 19
Heptares Therapeutics Ltd. 20
Omeros Corporation 21
Nicotine Addiction - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 29
Drug Profiles 31
(oxazepam + metyrapone) - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
AT-1001 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Drugs to Inhibit FAAH for CNS Disorders - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
encenicline hydrochloride - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
OMS-405 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
OMS-527 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
SLV-330 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Vaccine for Nicotine Addiction - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Vaccine for Nicotine Addiction - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Nicotine Addiction - Recent Pipeline Updates 46
Nicotine Addiction - Dormant Projects 50
Nicotine Addiction - Discontinued Products 51
Nicotine Addiction - Product Development Milestones 52
Featured News & Press Releases 52
Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction 52
May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors 52
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables

Number of Products under Development for Nicotine Addiction, H1 2015 8
Number of Products under Development for Nicotine Addiction - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Nicotine Addiction - Pipeline by AbbVie Inc., H1 2015 16
Nicotine Addiction - Pipeline by Astraea Therapeutics, LLC, H1 2015 17
Nicotine Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H1 2015 18
Nicotine Addiction - Pipeline by FORUM Pharmaceuticals Inc., H1 2015 19
Nicotine Addiction - Pipeline by Heptares Therapeutics Ltd., H1 2015 20
Nicotine Addiction - Pipeline by Omeros Corporation, H1 2015 21
Assessment by Monotherapy Products, H1 2015 22
Assessment by Combination Products, H1 2015 23
Number of Products by Stage and Target, H1 2015 25
Number of Products by Stage and Mechanism of Action, H1 2015 27
Number of Products by Stage and Route of Administration, H1 2015 28
Number of Products by Stage and Molecule Type, H1 2015 30
Nicotine Addiction Therapeutics - Recent Pipeline Updates, H1 2015 46
Nicotine Addiction - Dormant Projects, H1 2015 50
Nicotine Addiction - Discontinued Products, H1 2015 51